作者
Sophie Leboulleux,Claire Bournaud,C. Chougnet,Livia Lamartina,Slimane Zerdoud,Christine Do Cao,Bogdan Catargi,Inna Dygai,A. Kelly,Marie‐Luce Barge,Pierre Véra,Daniéla Rusu,Olivier Schneegans,Julie Roux,Perrine Raymond,Danielle Benisvy,Marie‐Claude Eberlé,Sophie Giraud,Camila Nascimento,D. Bastié,Anne‐Laure Giraudet,Stéphane Bardet,Nathalie Le Moullec,N. Roudaut,D. Drui,Yann Godbert,M. Zalzali,A. Drutel,Olivier Morel,Fritz-Line Vélayoudom,Abir Al Ghuzlan,Martin Schlumberger,Camille Buffet,Isabelle Borget
摘要
ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph nodes that cannot be assessed in the absence of neck dissection]), showed the non-inferiority of a follow-up strategy without radioactive iodine (
爱静静
浅尝离白
嗯哼
寻道图强
sutharsons
寒冷苗条
YifanWang
冷傲的傲霜
沉默的小天鹅
酷波er
杳鸢
sx
cc
加菲丰丰
司徒文青
汉堡包
勤劳的忆寒
充电宝
小二郎
情怀
皖公网安备34019202002308
